{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:02:34Z","timestamp":1762459354939,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T00:00:00Z","timestamp":1450915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00125-015-3845-8","type":"journal-article","created":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T01:14:55Z","timestamp":1450919695000},"page":"700-708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes"],"prefix":"10.1007","volume":"59","author":[{"given":"Elza","family":"Muscelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenno","family":"Astiarraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Barsotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freimut","family":"Schliess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leszek","family":"Nosek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Heise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uli C.","family":"Broedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Juergen","family":"Woerle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ele","family":"Ferrannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,24]]},"reference":[{"key":"3845_CR1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91:733\u2013794","journal-title":"Physiol Rev"},{"key":"3845_CR2","doi-asserted-by":"crossref","first-page":"C14","DOI":"10.1152\/ajpcell.00388.2010","volume":"300","author":"CS Hummel","year":"2011","unstructured":"Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM (2011) Glucose transport by human renal Na+\/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 300:C14\u2013C21","journal-title":"Am J Physiol Cell Physiol"},{"key":"3845_CR3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"V Vallon","year":"2011","unstructured":"Vallon V, Platt KA, Cunard R et al (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104\u2013112","journal-title":"J Am Soc Nephrol"},{"key":"3845_CR4","unstructured":"Boehringer Ingelheim International GmbH (2015). Jardiance (empagliflozin). Summary of product characteristics. Available from www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002677\/WC500168592.pdf . Accessed 27 Apr 2015"},{"key":"3845_CR5","unstructured":"AstraZeneca AB (2015). Forxiga (dapagliflozin). Summary of product characteristics. Available from www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002322\/WC500136026.pdf . Accessed 27 Apr 2015"},{"key":"3845_CR6","unstructured":"Janssen-Cilag International NV (2015). Invokana (canagliflozin). Summary of product characteristics. Available from www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002649\/WC500156456.pdf . Accessed 27 Apr 2015"},{"key":"3845_CR7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40265-014-0204-x","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM, Dungo RT (2014) Ipragliflozin: first global approval. Drugs 74:611\u2013617","journal-title":"Drugs"},{"key":"3845_CR8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40265-014-0229-1","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM, Prossler JE (2014) Tofogliflozin: first global approval. Drugs 74:939\u2013944","journal-title":"Drugs"},{"key":"3845_CR9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s40265-014-0230-8","volume":"74","author":"A Markham","year":"2014","unstructured":"Markham A, Elkinson S (2014) Luseogliflozin: first global approval. Drugs 74:945\u2013950","journal-title":"Drugs"},{"key":"3845_CR10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2012.58","volume":"92","author":"B Zambrowicz","year":"2012","unstructured":"Zambrowicz B, Freiman J, Brown PM et al (2012) LX4211, a dual SGLT1\/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 92:158\u2013169","journal-title":"Clin Pharmacol Ther"},{"key":"3845_CR11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/dom.12460","volume":"17","author":"NB Amin","year":"2015","unstructured":"Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM (2015) Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab 17:591\u2013598","journal-title":"Diabetes Obes Metab"},{"key":"3845_CR12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/dom.12393","volume":"17","author":"AP Sykes","year":"2015","unstructured":"Sykes AP, Kemp GL, Dobbins R et al (2015) Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab 17:98\u2013101","journal-title":"Diabetes Obes Metab"},{"key":"3845_CR13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Solini A (2012) SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8:495\u2013502","journal-title":"Nat Rev Endocrinol"},{"key":"3845_CR14","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/dom.12307","volume":"16","author":"A Liakos","year":"2014","unstructured":"Liakos A, Karagiannis T, Athanasiadou E et al (2014) Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 16:984\u2013993","journal-title":"Diabetes Obes Metab"},{"key":"3845_CR15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2042018814560735","volume":"6","author":"A Liakos","year":"2015","unstructured":"Liakos A, Karagiannis T, Bekiari E, Boura P, Tsapas A (2015) Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 6:61\u201367","journal-title":"Ther Adv Endocrinol Metab"},{"key":"3845_CR16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40265-014-0225-5","volume":"74","author":"G Plosker","year":"2014","unstructured":"Plosker G (2014) Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 74:807\u2013824","journal-title":"Drugs"},{"key":"3845_CR17","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/dom.12185","volume":"15","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Seman LJ, Jelaska A et al (2013) Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 15:1154\u20131160","journal-title":"Diabetes Obes Metab"},{"key":"3845_CR18","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.2337\/dc13-0663","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Berk A, Hantel S et al (2013) Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 36:4015\u20134021","journal-title":"Diabetes Care"},{"key":"3845_CR19","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","volume":"37","author":"HU H\u00e4ring","year":"2014","unstructured":"H\u00e4ring HU, Merker L, Seewaldt-Becker E et al (2014) Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37:1650\u20131659","journal-title":"Diabetes Care"},{"key":"3845_CR20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S et al (2014) Metabolic response to sodium-glucose co-transporter-2 inhibition in type 2 diabetic patients. J Clin Invest 124:499\u2013508","journal-title":"J Clin Invest"},{"key":"3845_CR21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G et al (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124:509\u2013514","journal-title":"J Clin Invest"},{"key":"3845_CR22","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.2337\/db11-0571","volume":"60","author":"E Mutel","year":"2011","unstructured":"Mutel E, Gautier-Stein A, Abdul-Wahed A et al (2011) Control of blood glucose in the absence of hepatic glucose production during prolonged fasting in mice: induction of renal and intestinal gluconeogenesis by glucagon. Diabetes 60:3121\u20133131","journal-title":"Diabetes"},{"key":"3845_CR23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","volume":"58","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58:429\u2013442","journal-title":"Diabetologia"},{"key":"3845_CR24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMcibr1409796","volume":"371","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E (2014) The target of metformin in type 2 diabetes. N Engl J Med 371:1547\u20131548","journal-title":"N Engl J Med"},{"key":"3845_CR25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.clpt.6100034","volume":"81","author":"A Gastaldelli","year":"2007","unstructured":"Gastaldelli A, Casolaro A, Pettiti M et al (2007) Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. Clin Pharmacol Ther 81:205\u2013212","journal-title":"Clin Pharmacol Ther"},{"key":"3845_CR26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ajcn\/33.1.27","volume":"33","author":"PE Watson","year":"1980","unstructured":"Watson PE, Watson ID, Batt RD (1980) Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 33:27\u201339","journal-title":"Am J Clin Nutr"},{"key":"3845_CR27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0169-2607(02)00097-4","volume":"71","author":"A Mari","year":"2003","unstructured":"Mari A, Stojanovska L, Proietto J, Thorburn AW (2003) A circulatory model for calculating non-steady-state glucose fluxes. Validation and comparison with compartmental models. Comput Methods Prog Biomed 71:269\u2013281","journal-title":"Comput Methods Prog Biomed"},{"key":"3845_CR28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0026-0495(88)90110-2","volume":"37","author":"E Ferrannini","year":"1988","unstructured":"Ferrannini E (1988) The theoretical bases of indirect calorimetry: a review. Metabolism 37:287\u2013301","journal-title":"Metabolism"},{"key":"3845_CR29","doi-asserted-by":"crossref","first-page":"E1159","DOI":"10.1152\/ajpendo.00093.2002","volume":"283","author":"A Mari","year":"2002","unstructured":"Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and oral glucose tests for assessment of \u03b2-cell action: modelling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159\u2013E1166","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3845_CR30","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2337\/diabetes.41.3.368","volume":"41","author":"E Cauter Van","year":"1992","unstructured":"Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368\u2013377","journal-title":"Diabetes"},{"key":"3845_CR31","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.diabres.2014.08.004","volume":"106","author":"T Wu","year":"2014","unstructured":"Wu T, Thazhath SS, Bound MJ, Jones KL, Horowitz M, Rayner CK (2014) Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity? Diabetes Res Clin Pract 106:e3\u2013e6","journal-title":"Diabetes Res Clin Pract"},{"key":"3845_CR32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.metabol.2010.01.001","volume":"60","author":"J Cuthbertson","year":"2011","unstructured":"Cuthbertson J, Patterson S, O\u2019Harte FP, Bell PM (2011) Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism 60:52\u201356","journal-title":"Metabolism"},{"key":"3845_CR33","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","volume":"38","author":"G Ferrannini","year":"2015","unstructured":"Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E (2015) Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition. Diabetes Care 38:1730\u20131735","journal-title":"Diabetes Care"},{"key":"3845_CR34","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"AL Peters","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB et al (2015) Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38:1687\u20131693","journal-title":"Diabetes Care"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-015-3845-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-015-3845-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-015-3845-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T18:58:21Z","timestamp":1567450701000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-015-3845-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,24]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["3845"],"URL":"https:\/\/doi.org\/10.1007\/s00125-015-3845-8","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"type":"print","value":"0012-186X"},{"type":"electronic","value":"1432-0428"}],"subject":[],"published":{"date-parts":[[2015,12,24]]}}}